Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a)

Published byJohan Budiono Modified over 5 years ago

Similar presentations

Presentation on theme: "Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a)"— Presentation transcript:

1 Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk  Benoit J. Arsenault, PhD, Francine Petrides, PhD, Fatiha Tabet, PhD, Weihang Bao, PhD, G. Kees Hovingh, MD, PhD, S. Matthijs Boekholdt, MD, PhD, Stéphane Ramin-Mangata, BSc, Olivier Meilhac, PhD, David DeMicco, PharmD, Kerry-Anne Rye, PhD, David D. Waters, MD, John J.P. Kastelein, MD, PhD, Philip Barter, MD, PhD, Gilles Lambert, PhD  Journal of Clinical Lipidology  Volume 12, Issue 1, Pages (January 2018) DOI: /j.jacl Copyright © 2017 National Lipid Association Terms and Conditions

2 Figure 1 Plasma PCSK9 levels at baseline in patients with or without type II diabetes in the entire study sample and in patients separated on the basis of atorvastatin dose. ∗Significantly different from atorvastatin 10 mg group in patients without type II diabetes. #Significantly different from atorvastatin 10 mg group in patients with type II diabetes. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2017 National Lipid Association Terms and Conditions

3 Figure 2 Plasma Lp(a) levels at baseline in patients with or without type II diabetes in the entire study sample and in patients separated on the basis of atorvastatin dose. ∗Significantly different from atorvastatin 10 mg group in patients without type II diabetes. #Significantly different from atorvastatin 10 mg group in patients with type II diabetes. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2017 National Lipid Association Terms and Conditions

4 Figure 3 Changes in plasma PCSK9 levels after 3 months on placebo or torcetrapib in patients with and without type II diabetes. ∗Significantly different from baseline. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2017 National Lipid Association Terms and Conditions

5 Figure 4 Changes in plasma Lp(a) levels after 3 months on placebo or torcetrapib in patients with and without type II diabetes. ∗Significantly different from baseline. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2017 National Lipid Association Terms and Conditions

Download ppt "Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a)"

Similar presentations

Philip J. Barter, et al. Circulation 2011;124:555-562.

Philip J. Barter, et al. Circulation 2011;124:
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes 

The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes 
Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,
Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.
2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?  Sripal Bangalore, MD,

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?  Sripal Bangalore, MD,
Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
An assessment by the Statin Cognitive Safety Task Force: 2014 update

An assessment by the Statin Cognitive Safety Task Force: 2014 update
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.
An assessment by the Statin Liver Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update
2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult  Todd J.

2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult  Todd J.
Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial  John J.P.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial  John J.P.
Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,
Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,
A review of PCSK9 inhibition and its effects beyond LDL receptors

A review of PCSK9 inhibition and its effects beyond LDL receptors
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C- III levels in patients from the MARINE and ANCHOR studies  Christie.

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C- III levels in patients from the MARINE and ANCHOR studies  Christie.
Predictors of first-year statin medication discontinuation: A cohort study  Heli Halava, MD, Risto Huupponen, MD, PhD, Jaana Pentti, BSc, Mika Kivimäki,

Predictors of first-year statin medication discontinuation: A cohort study  Heli Halava, MD, Risto Huupponen, MD, PhD, Jaana Pentti, BSc, Mika Kivimäki,

Similar presentations

Ads by Google